C3H/He-Tg(LCKprBCL2)36Sjk/J

Stock number: 002427
Product name: lck^Pr-bcl-2
Research areas: Apoptosis Research, Cancer Research, Immunology, Inflammation and Autoimmunity Research

Description

These lck^Pr-bcl-2 mice express a transgene containing human apoptosis regulator (BCL2) cDNA and are resistant to apoptosis induced by glucocorticoid treatment, radiation treatment, or anti-CD3 treatment.

Detailed description

Hemizygotes carrying the human LCKprBCL2 transgene display normal architecture of all lymphoid organs to 10 weeks of age. They show an increased percentage of CD3^hi/TCR^hi and CD4^-8⁺ thymocytes with a decreased percentage in CD3^lo T cells. CD8⁺ cells and the total percentage of T cells are increased in the spleen and lymph nodes. Mice are resistant to apoptosis induced by glucocorticoid treatment, by radiation treatment, or by anti-CD3 treatment. Malignant lymphoma develop in hemizygotes at approximately 18 months of age. Hemizygous BCL2 transgenic mice are fertile.

Allele

Symbol: Tg(LCKprBCL2)36Sjk
Name: transgene insertion 36, Stanley J Korsmeyer
MGI accession ID: MGI:2447592
Generation method: Transgenic
Attributes: Inserted expressed sequence; Humanized sequence
Marker symbol: Tg(LCKprBCL2)36Sjk
Marker name: transgene insertion 36, Stanley J Korsmeyer
Chromosome: UN
Strain of origin: Not Specified
Expressed genes: BCL2,BCL2, apoptosis regulator,human
Molecular note: The transgene consists of 0.75 kb of Lck proximal promoter sequences (active in lymphoid tissues) and 3.2 kb of human BCL2 cDNA. Introns, exons, and polyadenylation sequences from the human growth hormone gene consitutes the 3' untranslated region of the construct. Transgene expression in the thymus, lymph nodes, and spleen was verified by Western blot analysis and immunohistochemistry. Seven transgenic lines were established with lines 7, 17, and 36 expressing the transgene at high levels.